Mark McDade

Mr. McDade is co-founder and Managing Partner of Qiming Venture Partners US, which was started in January 2017. Prior to Qiming, Mr. McDade was Executive Vice President, Chief Operating Officer at UCB. He led UCB’s worldwide Geographic Operations, Established Brands, Technical Operations and Business Development while based in Brussels. He joined UCB’s Executive Committee in 2008. From 2002 until late 2007, Mr. McDade served as CEO and a director of PDL Biopharma, an antibody-based biotech located in Redwood City, CA. Prior to PDL, he served as CEO of Signature Bioscience, located in San Francisco, CA. Mr. McDade was founder and a director of Seattle-based Corixa Corporation, where he served as Chief Operating Officer from September 1994 to December 1998 and as President and Chief Operating Officer from January 1999 until his departure in late 2000 to join Signature. Before co-founding Corixa, Mr. McDade was COO of Boehringer Mannheim Therapeutics, the bio-pharmaceutical division of Corange, and prior to that held several positions at Sandoz Ltd. Including business development, product management and general management. Mr. McDade serves on the Board of directors of Dermira (DERM) and Aimmune Therapeutics (AIMT). He received a B.A. from Dartmouth College and an M.B.A. from the Harvard Business School.